Healthcare Global Enterprises · NSE: HCG · BSE: 539787

Q3 FY22 results · Oct–Dec 2021

Healthcare Global Enterprises reported revenue from operations of ₹358.06 crore (up 30.7% from Q3 FY21) and net loss of ₹49.80 crore for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	358.06	274.01	+30.7%	351.96	+1.7%
Other income	2.92	5.82	−49.8%	3.30	−11.5%
Total income	360.98	279.83	+29.0%	355.26	+1.6%
Profit before share of associates & JVs and tax	(46.13)	(35.63)	Loss widened	143.91	Turned loss
Share of profit/(loss) of associates & JVs	(0.01)	0.24		(2.00)
Net profit for the period	(49.80)	(34.73)	Loss widened	98.99	Turned loss
Attributable to shareholders of the company	(45.78)	(29.25)	Loss widened	103.09	Turned loss
EPS, basic (₹)	(3.55)	(2.33)	not comparable	8.22	not comparable
Net margin (%)	-13.9	-12.7		28.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	215.51	164.06	+31.4%	215.66	−0.1%
Other income	1.97	8.28	−76.2%	1.54	+27.9%
Total income	217.48	172.34	+26.2%	217.20	+0.1%
Profit before tax	(37.86)	(13.83)	Loss widened	132.70	Turned loss
Net profit for the period	(39.13)	(13.01)	Loss widened	93.90	Turned loss
EPS, basic (₹)	(3.03)	(1.04)	not comparable	7.49	not comparable
Net margin (%)	-18.2	-7.9		43.5

Consolidated

Filed with BSE: 10 Feb 2022, 20:31 IST
Board meeting: 10 Feb 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 10 Feb 2022, 20:31 IST
Board meeting: 10 Feb 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE